Bruce Turner
Corporate Officer/Principal at IMMUNOME, INC.
Net worth: 603 198 $ as of 29/04/2024
Profile
Bruce Turner is the founder of Gennao Bio, Inc. (founded in 2020) where he holds the title of Director, and Talos Surgical (founded in 2023) where he holds the title of Chairman.
He is currently the President, CEO, Secretary, Treasurer & Director at Xanadu Bio Inc. (since 2021) and the Chief Strategy Officer at Immunome, Inc. (since 2023).
Previously, he worked as a Managing Director at Boxer Capital LLC (2017-2021), a Principal at Hoffman-La Roche, Inc. (2013-2017), and as the Chief Financial & Strategy Officer at MorphImmune, Inc. (2023).
Dr. Turner obtained a doctorate degree from the University of Pennsylvania and the University of Pennsylvania Medical Center, and an undergraduate degree from The University of Chicago.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUNOME, INC.
0.07% | 01/10/2023 | 42,300 ( 0.07% ) | 603 198 $ | 29/04/2024 |
Bruce Turner active positions
| Companies | Position | Start |
|---|---|---|
| IMMUNOME, INC. | Corporate Officer/Principal | 01/10/2023 |
Gennao Bio, Inc.
 Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Founder | 30/04/2020 |
| Xanadu Bio Inc. | Chief Executive Officer | 30/06/2021 |
Former positions of Bruce Turner
| Companies | Position | End |
|---|---|---|
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Director of Finance/CFO | 30/09/2023 |
Boxer Capital LLC
 Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | Corporate Officer/Principal | 31/12/2020 |
| Hoffman-La Roche, Inc. | Corporate Officer/Principal | 31/12/2016 |
Training of Bruce Turner
| The University of Chicago | Undergraduate Degree |
| University of Pennsylvania Medical Center | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Gennao Bio, Inc.
Gennao Bio, Inc. Pharmaceuticals: MajorHealth Technology Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
| Xanadu Bio Inc. | |
Boxer Capital LLC
Boxer Capital LLC Investment ManagersFinance Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California. | Finance |
| Hoffman-La Roche, Inc. | Health Technology |
- Stock Market
- Insiders
- Bruce Turner
